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Abstract 
Aims 
Folic acid supplementation lowers total plasma homocysteine (tHcy) and improves 
endothelial function in individuals with coronary artery disease (CAD) and in those 
with additional CAD risk factors. We assessed whether endothelial function is 
impaired in healthy subjects with hyperhomocysteinemia but without other CAD risk 
factors and whether folic acid supplementation improves endothelial function in these 
subjects.  
Methods 
Flow-mediated dilatation (FMD) of the brachial artery was performed on 26 healthy 
subjects, age 49 ± 2 yrs (mean + SEM), with high tHcy (15.6 ± 1.5 µmol/l) and 16 
healthy age-matched subjects with low tHcy (7.9 ± 0.6 µmol/l) (p<0.001). High tHcy 
subjects were then randomised to receive 5mg/day of folic acid or placebo for 8 
weeks in a double-blind cross-over trial with 4-week washout.  
Results 
FMD was not associated with tHcy and was not different between high and low tHcy 
groups (7.0 ± 0.6% vs 6.6 ± 1.2%, p=0.76). Treatment with folic acid decreased tHcy 
by 34% in hyperhomocysteinemic subjects (p=0.02 vs placebo) but had no effect on 
FMD (+0.5 ± 0.6% vs –0.7 ± 0.5%, p=0.17 vs placebo).  
Conclusion 
In healthy subjects with hyperhomocysteinemia but without additional cardiovascular 
risk, endothelial function is unimpaired and folic acid supplementation has no 
additional effect. 
Keywords: 
Endothelial function, Folic acid supplementation, Homocysteine, Atherosclerosis, 
Ultrasound  
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INTRODUCTION 
Hyperhomocysteinemia is now considered an independent and graded risk factor for 
atherosclerotic vascular disease (1), and for mortality in patients with coronary artery 
disease (CAD) (2). Mildly elevated levels of homocysteine occur commonly in the 
general population as a result of either genetic influences or sub-optimal nutrition 
(3;4). Since supplementation with folic acid lowers total plasma homocysteine (tHcy) 
in both healthy individuals and those with existing CAD (5), folic acid 
supplementation may be a simple and effective method for both primary and 
secondary prevention of CAD.   
Experimental evidence suggests that hyperhomocysteinemia may cause 
vascular damage and dysfunction (4;6) and indeed, hyperhomocysteinemia has been 
associated with impaired endothelial function in healthy volunteers (7;8). 
Supplementation with folic acid lowers homocysteine and also improves endothelial 
function in subjects with CAD (9-11)  or those with other risk factors for CAD (12). 
However the effects of homocysteine lowering on endothelial function in healthy 
subjects with mild to moderate hyperhomocysteinemia, but without other clearly 
defined risk factors is still uncertain. Whilst some studies have shown an 
improvement (13;14), others have found no change (15). A variable effect of folic 
acid supplementation may be a consequence of folic acid acting independently of 
reductions in homocysteine (16;17). In studies in which improved endothelial 
function has occurred, the changes have usually not been associated with the actual 
decreases in tHcy (9;10;14;16;18;19) In addition, folic acid or its active form, 5-
methyltetrahydrofolate, restores endothelial function in familial 
hypercholesterolaemic subjects without hyperhomocysteinemia (12;18). In-vitro 
studies suggest that these improvements in endothelial function, rather than occurring 
directly via a reduction in homocysteine, may occur as either a direct or indirect 
reduction in oxidative stress (16;18). 
This study assessed whether healthy subjects with basal tHcy levels in the 
upper quartile of a West Australian population but without other CAD risk factors had 
impaired endothelial function. We also determined whether the lowering of 
homocysteine with high dose (5mg/day) folic acid supplementation for  
8 weeks, would improve endothelial function in these subjects.  
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METHODS 
Subjects 
Subjects were original participants in a random electoral survey of 2000 people from 
the metropolitan area of Perth, Western Australia (20). From these invited subjects, a 
total of 1111 (558 men, 553 women), age 52 ± 13 yrs (mean ± SD; range 27 to 77 
yrs), were assessed between June 1995 and December 1996 for tHcy and standard 
cardiovascular risk factors (3), and then divided into sex-specific quartiles according 
to their tHcy. We randomly selected 26 healthy male and female subjects from those 
in the upper tHcy quartile (men> 14.4; women>12.8 µmol/l) who were also aged 
between 35-60 years, who had never smoked, had a total cholesterol < 6.0 mmol/l, 
were non-diabetic, normotensive (systolic blood pressure < 140 mmHg), were not 
receiving medication for cholesterol, blood pressure, or asthma and who did not take 
vitamin supplements. Sixteen healthy age-matched subjects in the bottom tHcy 
quartile (men< 10.5; women<8.4 µmol/l) were recruited as a control population and 
were also used to assess the reproducibility of the brachial artery ultrasound 
technique. However they were not used in the folic acid intervention phase of the 
study. The study was approved by the Institutional Ethics Committee of the 
University of Western Australia and conforms with the principles outlined in the 
Declaration of Helsinki (21). 
 
Study design 
The intervention study was performed in the hyperhomocysteinemic subjects (n=26) 
in a double-blinded cross-over fashion with subjects randomly allocated to either 
placebo or folic acid (5mg/day) for 8 weeks followed by a 4-week washout, then 
crossed over to either folic acid or placebo for the final 8 weeks. Subjects were tested 
at the beginning and end of each 8-week intervention period. On each occasion 
subjects attended after a 12-hour fast for blood tests, and a brachial artery ultrasound 
study to determine endothelium-dependent and endothelium-independent function.  
Subjects were instructed to avoid changing their normal diet for the duration of the 
study and on the morning of their visits to only drink water. The control participants 
with low tHcy (n=16) had the same blood tests, and brachial ultrasound studies were 
performed on 2 visits one week apart without any treatment or change of diet between 
visits in order to assess the reproducibility of the technique. 
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Laboratory measurements 
Fasting venous blood samples were obtained at each visit for subjects in both the high 
and low homocysteine groups. Samples were collected into vacutainers containing 
EDTA or heparin for the measurement of red cell folate (RCF), vitamins B6 and B12 
and total plasma homocysteine (tHcy).   The samples were centrifuged shortly after 
venipuncture. For tHcy assays, the plasma was separated, transported on ice, and 
stored at –700 until assay. tHcy was determined by reverse-phase high performance 
liquid chromatography after treatment with tributylphosphine, deproteinization, and 
fluorogenic derivatization by the method of Araki and Sako (22). The inter-assay 
coefficient of variation (CV) is 6% in our laboratory (23). RCF was measured by a 
procedure based upon ion capture technology (AxSYM Folate, Abbott Laboratories, 
Illinois). The inter-assay CV is 4.1 % and the mean (normal range) 331.4 ng/mL 
(180.4-617.5 ng/mL). Vitamin B6 (pyridoxal –5’-phosphate) was measured by 
microbial assay (24). The inter-assay CV is 7.1 % and the normal range for healthy 
middle-aged subjects 21.6-66.0 nmol/L. Vitamin B12 was determined from serum 
obtained at baseline using a micro particle enzyme immunoassay (AxSYM B12, 
Abbott Laboratories, Illinois).  The inter-assay CV is 6.8 % and the mean (normal 
ranges) for healthy subjects 474 pg/mL (100 - 2437 pg/mL). At baseline, total 
cholesterol, HDL cholesterol and triglyceride levels were determined enzymatically 
with a Hitachi 747 autoanalyser. LDL cholesterol was calculated using the method by 
Friedwald et al. (25). 
 
Brachial artery ultrasound 
Flow-mediated dilatation (FMD) and glyceryl trinitrate-mediated dilatation 
(GTNMD) were used to assess endothelium-dependent and endothelium-independent 
function respectively. The technical aspects of the ultrasound procedure used for the 
assessment of FMD and GTNMD have been described previously by Celermajer et al 
(26). Briefly, 2-dimensional B-mode ultrasound images of the lumen/arterial wall 
interface of the left-hand brachial artery were obtained in the distal third of the upper 
arm using a high resolution 12 MHz linear array transducer (Sequoia, Accuson 
instruments, Colorado, USA). Baseline scans assessing vessel diameter were recorded 
over one minute.  Arterial flow velocity was measured using a pulsed Doppler signal 
at 700 to the vessel with the range gate (1.5mm) in the centre of the artery. A rapid 
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inflation/deflation pneumatic cuff, previously placed around the forearm immediately 
distal to the humeral epicondyle, was inflated to 250 mm Hg for 4.5 min to induce 
FMD. Recordings commenced 30 sec prior to cuff deflation and continued for 90 
seconds after cuff deflation.  After 10 mins, a second baseline scan was recorded. This 
was followed by sublingual administration of glyceryl trinitrate (400 µg) and 
recording of images for a further 5 minutes. All images were recorded on super-VHS 
videotape (Sony MQSE 180), for retrospective analysis. Baseline volume flow was 
calculated by multiplying the mean velocity time integral of the Doppler flow signal 
for 2 consecutive pulse waves, by the heart rate and vessel cross-sectional area. Peak 
hyperaemic response was calculated using 2 consecutive pulse waves within the first 
15 seconds following cuff deflation, and dividing by baseline flow. FMD and 
GTNMD measurements were performed using traditional manual analysis techniques 
with ultrasonic callipers (26). The mean of 2 observers measurements were used for 
all scans. Observers were blinded to patient group and treatment order. 
 
Reproducibility of brachial artery ultrasound 
Ultrasound scans were repeated one week later on subjects with low tHcy (n=16) 
under the same conditions as their first scan. Values for each visit were calculated as 
the mean measurement of 2 observers and within-subject variability of FMD and 
GTNMD was calculated as the between-visits CV.  
 
Statistical analysis 
Data were analysed using SPSS (SPSS Inc, Chicago). Differences in baseline 
characteristics between subjects with high and low tHcy, and between the 2 groups of 
subjects with high tHcy were compared with unpaired t-tests. Effects of treatment  
and placebo were assessed using a paired t-test on the changes during each period. 
Treatment period interactions were assessed for RCF, tHcy, FMD and GTNMD by 
comparing changes in the 2 groups during the two treatment periods with an unpaired 
t-test. Linear regression analysis was conducted to examine the relationships between 
RCF, tHcy, and FMD. Differences were considered significant at a p value <0.05. All 
variables were tested for normality using histograms and Kolmogorov-Smirnov 
statistics. Values are reported as mean ± SE except for changes due to treatment, 
which are reported as mean (95% confidence interval). FMD and GTNMD responses 
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were calculated as the percent increases from baseline diameter. CV’s for FMD and 
GTNMD were calculated as the pooled SD for replicates ÷ mean. The statistical 
power for a cross-over study using the ultrasound technique was determined using an 
MS-DOS based statistical power calculation program (POWER) (27). Power was 
calculated for detecting an absolute 2% change in FMD. 
 
RESULTS 
Within-subject reproducibility of brachial artery ultrasound 
In the control population with low tHcy (n=16), the mean (± SD) %FMD for visits 1 
and 2 were 6.6 ± 4.8 % and 6.4 ± 3.0 %, respectively. The combined mean was 6.5 ± 
3.8 % and the mean absolute difference between visits was 1.6 ± 1.9 %. The between 
visit CV for %FMD was 24.6 % and the Pearson correlation coefficient r=0.91. The 
power to detect an absolute 2% change in FMD in the cross-over study was 83% at an 
alpha of 0.05.  
The mean (± SD) %GTN for visits 1 and 2 were 18.4 ± 6.6 % and 19.4 ± 8.5 
%, respectively. The combined mean was 19.6 ± 8.0 % and the mean absolute 
difference between visits was 1.5 ± 1.0 %. The between visit CV for %GTN was 
7.7% and the Pearson correlation coefficient r=0.96. The power to detect an absolute 
2% change in GTN in the cross-over study was 99.4% at an alpha of 0.05. 
 
Subject characteristics 
Table 1 shows the characteristics of all subjects at baseline. Subjects with high tHcy 
had higher levels of tHcy (15.6 ± 1.5 µmol/l vs 7.9 ± 0.6 µmol/l, p<0.001), and 
plasma creatinine (91 ± 3 vs 74 ± 3, p<0.001), but lower levels of RCF (332 ± 21 
ng/ml vs 425 ± 41 ng/ml, p=0.03) than those with low tHcy. However, there were no 
significant differences in other baseline clinical variables. At baseline, tHcy was 
inversely associated with RCF amongst all subjects (r=-0.4, p<0.01) and also amongst 
the subjects with high tHcy alone (r=-0.38, p=0.05). However, there were no 
associations between FMD and tHcy for all subjects (r=0.23, p=0.14) or for those 
with high tHcy alone (r=0.16, p=0.45). FMD, GTNMD, and hyperaemic responses 
were no different between the high and low tHcy subjects (Table 1). 
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Amongst subjects with high tHcy, there were no significant differences 
between the initial folic acid and placebo groups in their baseline characteristics 
including tHcy, RCF, FMD, GTNMD, and reactive hyperaemia (data not shown). .  
 
Effect of treatment 
Table 2 shows the effect of treatment in each group between visits 1 and 2, and 
between visits 3 and 4. When the results of both groups were combined (n=26),  
treatment with folic acid increased RCF by an average of 89% (+300 + 26 ng/mL) 
compared to a decrease of 8% (-33 + 26 ng/mL) during treatment with placebo 
(treatment minus placebo effect = 333 ng/mL (254, 411), p<0.001) . Similarly, tHcy 
decreased by an average of 34% (–5.0 + 1.6 µmol/l) with folic acid compared with a 
mean increase of 2% (+0.2 + 0.6 µmol/l) with placebo (treatment minus placebo 
effect = -5.2 µmol/l (-9.5, -1.0), p=0.02). However, folic acid had no effect on either 
FMD (treatment minus placebo effect = 1.2% (-0.5, 2.8), p=0.17) or GTNMD 
(treatment minus placebo effect = -0.4% (-3.4, 2.6), p=0.77) compared to placebo 
(Figure 1) and changes in tHcy during treatment were not significantly associated 
with changes in FMD (r=0.02, p=0.94). Following the 4-week washout period, RCF 
was significantly higher (499 ± 23 ng/ml vs 352 ± 34 ng/ml, p=0.002), and tHcy 
significantly lower (10.3 ± 0.5 µmol/l vs 13.6 ± 0.8 µmol/l, p=0.001) in the subjects 
who received treatment first compared to those who received placebo first (Table 2). 
However, no significant treatment-period interactions between the 2 groups occurred 
in any of the variables (Table 2). 
 
Discussion 
This study has demonstrated that endothelial function is not significantly impaired in 
healthy subjects with mild to moderate basal hyperhomocysteinemia but without other 
risk factors for CAD. In addition, 8-weeks of high-dose folic acid supplementation did 
not have any additional effect on endothelial function in this population despite 
substantial reductions in tHcy, increases in RCF, and sufficient statistical power to 
detect a small (2%) absolute change in FMD.  
Other studies have not clearly established whether basal elevation of tHcy is 
associated with impaired FMD in otherwise healthy subjects. Pullin et al (15) found 
no difference in FMD in healthy individuals with elevated tHcy who were 
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homozygous (TT) for the C677T mutation in the methylenetetrahydrofolate reductase 
gene compared to wild-type (CC) individuals with normal tHcy (15). By comparison, 
Woo et al (7) and Tawakol et al (8) reported that hyperhomocysteinemia was 
associated with impaired FMD in “healthy” subjects. Differences in clinical risk 
characteristics of the subjects such as smoking history (7), older-age (8) and higher 
tHcy levels (7) may explain the discordance in these data with our own findings and 
those of Pullin et al (15).  
The absence of endothelial dysfunction in our subjects despite 
hyperhomocysteinemia is also plausible in light of numerous reports showing the lack 
of an association between improvements in endothelial function and reductions in 
tHcy subsequent to folic acid supplementation (9;10;14;16;18;19). Similarly, 
improvements in FMD were not associated with reductions in either tHcy or free Hcy 
following either an acute dose (2 hours or 4 hours) or long-term administration (6 
weeks) of 5mg/day of folic acid in CAD patients (9). However, free plasma Hcy has 
been shown to be a significant independent predictor of FMD in another group of  
CAD patients (10),  
Our finding of no effect on FMD with high-dose folic acid supplementation in 
a healthy population is supported by Pullin et al. (15) using lower doses of folic acid 
(400µg/day) in healthy subjects with hyperhomocysteinemia in the presence of 
genetic mutations of methylenetetrahydroflate reductase. Thus, no improvement in 
FMD occurred despite increases in plasma folate and reductions in tHcy. Whilst their 
subjects only received 400µg of folic acid/day compared to our higher dose of 
5mg/day, this should have been sufficient to reduce tHcy levels maximally in most 
subjects (5).  
The disparate findings concerning the effects of folic acid on endothelial 
function in subjects with hyperhomocysteinemia may be a result of the presence or 
absence of CAD or other cardiovascular risk factors. Atherosclerotic vascular disease 
or added risk may be necessary before endothelial function is impaired as a 
consequence of hyperhomocysteinemia (28). For example, the combination of 
smoking and hyperhomocysteinemia appears to greatly increase cardiovascular risk 
(29), possibly via a synergistic effect on antioxidant defences (30). Accordingly, folic 
acid has been demonstrated to cause improvement of endothelial function in 
hyperhomocysteinemic patients with CAD (10;11). 
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Whilst small increases in FMD have been observed in studies of healthy 
subjects with hyperhomocysteinemia following high-dose folic acid supplementation, 
uncertainty exists regarding the subjects’ risk-profile (13,14).  Thus, in the study by 
Bellamy et al (13) using blood donors, the age of the “healthy” volunteers were not 
specified and they also allowed higher inclusion levels of blood pressure and serum 
cholesterol than in our study. In the other study by Woo et al (14) using Chinese 
subjects, their smoking status was not stated and serum cholesterol levels were not 
measured. In addition, neither of these two studies included control subjects without 
hyperhomocysteinemia to determine if endothelial function was impaired at baseline.  
Possibility exists for the acute effects of folic acid, rather than its 
homocysteine-lowering effects to be responsible for improvements in endothelial 
function. FMD was increased only 2 hours after consuming 5mg of folic acid, despite 
no change in tHcy (9). Likewise, folic acid or its active form, 5-
methyltetrahydrofolate, restores endothelial function in familial 
hypercholesterolaemic subjects without hyperhomocysteinemia (12;18). These effects 
may be a consequence of folic acid reducing LDL-induced eNOS increases in the 
generation of superoxide production (18) and/or enhancing NO synthesis by 
increasing the effectiveness of tetrahydrobiopterin (a co-factor for NO synthesis) on 
NO synthase uncoupling (17).  The acute effects of folic acid, may thus explain the 
improvements in endothelial function observed in healthy subjects with 
hyperhomocysteinemia who were instructed to take their folic acid supplement before 
attending for tests of vascular function (14). In our own study, subjects were 
requested to drink water only on the morning of their visits, thereby ensuring that  
chronic rather than  acute effects of folic acid supplementation were assessed. 
 The absence of any effects on endothelial function in this study are unlikely to 
have been due to the slight carry-over effects following folic acid washout since there 
was no significant treatment-period interaction. Although the washout period was not 
sufficient to normalise tHcy, it was sufficient for the studies of vascular function. In 
our study we assessed RCF, an indicator of long-term folate status, as opposed to 
plasma folate, which varies rapidly after folic acid intake. Whilst there was an 
association between RCF and tHcy at baseline, there were no associations between 
either RCF or tHcy and endothelial function. This supports our main findings that 
endothelial function is not necessarily impaired in healthy subjects with basal 
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hyperhomocysteinemia, and that in this case, reducing homocysteine does not have 
any additional effect on endothelial function.  
In conclusion, our results suggest that mild to moderate 
hyperhomocysteinemia alone does not cause endothelial dysfunction in healthy 
subjects in the absence of other cardiovascular risk factors. Folic acid 
supplementation may therefore not be beneficial in reducing cardiovascular risk in 
this section of the general population. 
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Age (years) 49 ± 2 50 ± 2 NS 
Male/Female 18/8 11/5 NS 
Homocysteine (µmol/l) 15.6 ± 1.5 7.9 ± 0.6 < 0.001 
BMI (kg/m2) 28.1 ± 1.0 25.2 ± 2.1 NS 
Waist/hip ratio 0.90 ± 0.06 0.87 ± 0.02 NS 
SBP (mm/Hg) 125 ± 2 129 ± 4 NS 
DBP (mm/Hg) 81 ± 2 87 ± 2 NS 
Total cholesterol (mmol/l) 5.3 ± 0.1 5.4 ± 0.2 NS 
LDL cholesterol (mmol/l) 3.2 ± 0.2 3.4 ± 0.2 NS 
HDL cholesterol (mmol/l) 1.39 ± 0.07 1.36 ± 0.06 NS 
Triglycerides (mmol/l) 1.27 ± 0.17 1.29 ± 0.16 NS 
Creatinine (µmol/l) 91 ± 3 74 ± 3 < 0.001 
Red cell folate (ng/mL) 332 ± 21 425 ± 41 0.03 
Vitamin B6 (nmol/L) 39 ± 5 44 ± 5 NS 
Vitamin B12 (pg/mL) 360 ± 21 386 ± 31 NS 
Flow-mediated dilatation (%) 7.0 ± 0.6 6.6 ± 1.2 NS 
GTN-mediated dilatation (%) 20.4 ± 0.9 18.4 ± 1.7 NS 
Basal blood flow (ml3/min) 29.3 ± 5.0 23.1 ± 3.1 NS 
Reactive hyperaemia (%) 786 ± 118 650 ± 104 NS 
Values are Mean ± SEM. 1Unpaired t-test 
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TABLE 2 
















Group 1 Placebo 14.9 ± 1.0 13.2 ± 0.9 -1.7 ± 0.50 Folic acid 13.6 ± 0.8 10.0 ± 0.7 -3.5 ± 0.6 
HCY 
Group 2 Folic acid 16.4 ± 3.0 9.8 ± 0.7 -6.6 ± 3.1 Placebo 10.3 ± 0.5 12.4 ± 1.0 2.1 ± 0.9 
NS 
         
        
        
  
Group 1 Placebo 338 ± 23 320 ± 29 -18 ± 19 Folic acid 352 ± 34 683 ± 52 331 ± 39 
RCF 
Group 2 Folic acid 326 ± 35 595 ± 37 269 ± 40 Placebo 499 ± 23 451 ± 48 -47 ± 48 NS 
   
Group 1 Placebo 6.5 ± 0.7 5.3 ± 0.7 -1.2 ± 0.6 Folic acid 6.5 ± 0.7 6.3 ± 1.0 -0.2 ± 0.6 
%FMD 
Group 2 Folic acid 7.5 ± 1.1 8.7 ± 1.3 1.2 ± 1.1 Placebo 8.0 ± 1.1 7.9 ± 1.2 -0.1 ±0.8 NS 
   
Group 1 Placebo 19.3 ± 1.2 19.0 ± 1.1 -0.3 ± 1.4 Folic acid 17.5 ± 1.0 19.7 ± 1.2 2.2 ± 1.3 
%GTN 
Group 2 Folic acid 21.6 ± 1.4 20.9 ± 2.0 -0.7 ± 1.7 Placebo 18.8 ± 1.4 20.5 ± 1.5 1.7 ± 1.5 NS 
 
1 Unpaired t-test, ∆1 vs ∆2 for placebo and ∆1 vs ∆2 for folic acid. 
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Figure Legend: Mean (± SEM) flow-mediated dilatation (FMD) and glyceryl-
trinitrate mediated dilatation (GTNMD) at the end of the placebo and folic acid phases 
of supplementation.   
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